Drug majors most profitable industry sector, report finds

14 November 2019

A new analysis from researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health reveals high levels of profitability among large drugmakers.

The researchers found that, even with a $1 trillion reduction in sales, brand-name drugmakers would represent the most profitable industry sector, and would be able to maintain current R&D investment levels.

The research, which analyses publicly-reported financial data and builds on previous research by the US Government Accountability Office and the Congressional Budget Office (CBO), suggests that the pharmaceutical industry has among the highest profit margins and returns of any industry group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical